The APOC3 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the widely used HEK293T human embryonic kidney cell line. This product provides a loss-of-function model for the APOC3 gene through CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool of edited alleles. The polyclonal format avoids clonal selection artifacts and is particularly suited for studies requiring population-level genetic diversity, such as drug screening and interaction proteomics. Researchers can employ these cells to examine apolipoprotein C-III biology without the constraints of a single clonal genotype.
HEK293T cells are an adherent epithelial line that stably expresses the SV40 large T antigen, facilitating high-level episomal replication of plasmids containing the SV40 origin. This feature, combined with their exceptional transfectability, makes them a preferred host for recombinant protein expression, lentiviral production, and transient overexpression experiments. While HEK293T cells do not recapitulate hepatocyte-specific lipoprotein metabolism, their clean genetic background and ease of manipulation provide a flexible platform for mechanistic dissection of individual gene function in a simplified eukaryotic environment.
APOC3 encodes apolipoprotein C-III, a key inhibitor of lipoprotein lipase (LPL) and hepatic lipase, which delays the clearance of triglyceride-rich lipoproteins such as chylomicrons and very-low-density lipoproteins (VLDL). Transcriptional control of APOC3 is exerted by nuclear receptors including PPAR?? and HNF4??, and is modulated by metabolic cues like insulin and glucose. Apolipoprotein C-III physically interacts with APOB, APOE, and LPL, forming a regulatory axis that governs plasma triglyceride levels. Disruption of APOC3 in this model lifts the inhibitory constraint on lipases, offering a defined system to interrogate protein?Cprotein interfaces and transcriptional regulation within this network.
Although HEK293T cells lack endogenous lipoprotein assembly and secretion pathways, their utility for heterologous reconstitution makes them a powerful tool for APOC3 research. The knockout background enables controlled reintroduction of wild-type or mutant APOC3 variants, supporting dissection of functional domains, post-translational modifications, and interaction surfaces. The polyclonal nature of the edited pool further broadens applicability, as it mimics the genetic variation relevant to population-based drug response studies, and allows unbiased identification of modulators that affect apolipoprotein C-III stability or complex formation.
These polyclonal knockout cells are amenable to a wide array of assays, including western blotting, RT-qPCR, co-immunoprecipitation, immunofluorescence, reporter gene analyses, and mass spectrometry-based interactomics. Co-expression of APOC3 with its regulatory partners or lipoprotein components can reconstitute parts of the triglyceride clearance machinery, enabling functional readouts such as LPL activity measurements. The model thus supports applications spanning APOC3 functional characterization, inhibitor screening, transcriptional regulation studies, and exploration of hypertriglyceridemia-associated mechanisms. For further inquiries or custom engineering, please contact Ascent Research.
